ONE Patient. ONE Room. 20 Reimbursable Programs. 📈

3-Minute

Alzheimer's

Assessment

Diabetes and Memory

DTC Alzheimer's Care Clinics®. Early detection of Alzheimer’s and dementia is critical in Primary Care Physician (PCP) clinics to distinguish cognitive decline from normal aging. Our Digital Cognitive Assessment is FDA-Registered and offer a fast, compliant, and scalable solution that outperforms traditional paper-based tests like the MoCA, MMSE, or Mini-Cog—especially in clinical efficiency, reimbursement potential (up to 8x ROI), and long-term patient tracking.

By adopting our 3-Minute Cognitive Assessment, you improve patient care, generate new revenue, and minimize the burden on your clinical team—all while staying ahead of your competitors. If you'd like to see a demo or learn more about integration into your workflow, just contact us and we’d be happy to help.

Before...

Alzheimer’s steals a lifetime of memories,

There’s early detection at DTC.

The 3-minute cognitive screening seamlessly transitions into a complete digital cognitive health solution—from initial screening to full monitoring—accessible on any computer, tablet, or smartphone.

Cognitive Assessment

19:06 Minutes

Note: 15 second audio delay after pressing play.

IMPORTANT

Q: Why is it critical for PCPs to use an FDA-Registered Cognitive Assessment—rather than one that is merely “validated”? (click down arrow for answer)

FDA-Registered tools meet rigorous standards for safety, efficacy, and reproducibility—essential when clinical decisions and reimbursement are on the line.
“Validated” tools may be supported by academic studies, but without FDA oversight, they may lack regulatory approval, standardization, or accepted use for billing CPT codes like 96132, 96136, or 99483.
Payers—including Medicare—may deny claims or claw back payments if the assessment used is not considered medically appropriate, regulated, or defensible in an audit.
Malpractice risk increases when diagnoses are based on tools not recognized by regulatory agencies.
For early detection of Alzheimer’s, dementia, or cognitive decline, FDA recognition ensures providers are using tools that align with national standards and are suitable for care planning and specialist referrals.

In short: Using a non-FDA-cleared tool could put your patients, revenue, and reputation at risk. DTC only supports platforms that are FDA-cleared or registered—to protect both the provider and the patient.

Neurotrack vs MMSE, Mini-Cog, and MoCA

Neurotrack Platform

DTC Screen™

1-Minute

A proprietary screener that accurately ensures medical necessity, screens for cognitive decline, and determines whether further evaluation is warranted.

Neurotrack Assessment

3-Minutes

The FDA-registered digital cognitive assessment is non-invasive and can be performed at the point of care for in-clinic or remote testing.

3-Minute Testing Enables Scalable Screening

Empowering PCPs in Dementia Prevention & Early Detection

Alzheimer's and Dementia are a growing public health concern, with Alzheimer’s disease affecting nearly one in nine adults over 65 in the U.S.. In primary care, the early signs of cognitive decline often present as mild cognitive impairment (MCI)—subtle but measurable deficits in memory, thinking, and decision-making. PCPs play a critical role in early identification, intervention, and risk reduction, helping patients optimize brain health before significant cognitive deterioration occurs.

Genetics, Lifestyle, and Modifiable Risk Factors

While genetics and family history influence cognitive decline, modifiable lifestyle factors significantly impact dementia risk. PCPs can guide patients in managing key risk factors, which include:

Obesity – Linked to chronic inflammation and metabolic disorders, increasing dementia risk.
Smoking – Contributes to vascular damage and reduced oxygenation to the brain.
Diabetes – Associated with insulin resistance and vascular complications, accelerating neurodegeneration.
Hypertension (High Blood Pressure) – A leading cause of vascular dementia and stroke-related cognitive decline.
High Cholesterol – Elevated midlife LDL cholesterol is strongly correlated with Alzheimer’s disease and cognitive impairment.

Cholesterol and Cognitive Decline

Recent studies highlight a strong link between cholesterol levels and cognitive health. High LDL ("bad") cholesterol and low HDL ("good") cholesterol contribute to brain plaque formation, reduced cerebral blood flow, and neuroinflammation. Addressing lipid management early can be a proactive strategy for dementia prevention in at-risk patients.

The PCP’s Role in Early Intervention

Since dementia progresses over decades, early action is key. PCPs can integrate cognitive screening into routine care to identify risk factors early and guide prevention strategies. Key interventions include:

Routine cognitive screening to track changes over time.
Lifestyle counseling on diet, exercise, and vascular health.
Medication management for cholesterol, diabetes, and hypertension.
Patient & caregiver education on modifiable risk factors.

The Value of Cognitive Screening in Primary Care

By incorporating evidence-based cognitive screening tools, PCPs can improve early detection, facilitate timely referrals, and enhance patient outcomes. Medicare and commercial insurance reimburse cognitive assessments, making them both a clinical necessity and a revenue-generating opportunity for primary care practices.

Take a proactive approach to brain health—integrate cognitive screening into your practice today.

80% of People with Alzheimer's have Insulin Resistance or Type 2 Diabetes

Neurotrack vs MoCA

Little to No Workflow

Diabetes Testing Centers™ (DTC) recognizes the critical importance of cognitive assessments for individuals with diabetes. As part of our comprehensive approach to diabetes care, we offer turnkey cognitive assessments to support healthcare providers in delivering high-quality care. Here's how DTC provides these assessments:

Incorporating Cognitive Assessments: Our programs are designed to include cognitive assessments as an integral component of diabetes care. We understand that cognitive health is closely linked to diabetes management, and we prioritize the well-being of our patients.
Streamlined Process: DTC offers a turnkey approach, streamlining the cognitive assessment process. This makes it easy for healthcare providers to integrate cognitive assessments into their practice without adding unnecessary complexity.
Comprehensive Reporting: We provide detailed and comprehensive reports based on the cognitive assessments. These reports offer insights into a patient's cognitive function, allowing healthcare providers to make informed decisions about care plans and interventions.

By providing turnkey cognitive assessments, DTC empowers healthcare providers to address the cognitive health needs of individuals with diabetes comprehensively. This approach supports the overall well-being of patients and enhances the quality of care in diabetes management.

Poorly Controlled Blood Sugar May Increase the Risk of Developing Alzheimer's

Schedule Below to Learn More

Page updated

Report abuse